MOVE.NASDAQMovano INC

425: Movano Restates Financials Post-Reverse Split, Faces Going Concern

Sentiment:

Financial Statement Restatement


Movano Inc. has re-published its audited financial statements for 2023 and 2024 to reflect a 1-for-10 reverse stock split effective October 10, 2025, alongside reporting continued significant losses and a going concern uncertainty.

Capital raiseThe company has an At-the-Market (ATM) issuance program with approximately $42.5 million remaining available to be issued and sold as of December 31, 2024.Management explicitly states the company expects to require additional financing to fund future planned operations.Plans to likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies.Previously raised approximately $7.5 million gross from an ATM program through December 31, 2024.Completed a $7.5 million public offering in February 2023.Completed a $9.2 million public offering in June 2023.Completed a $4.1 million public offering in November 2023.Completed a $24.1 million private placement in April 2024.
Worse than expectedThe company continues to report significant net losses ($23.727 million in 2024).The auditor's report explicitly highlights a "going concern uncertainty," indicating substantial doubt about the company's ability to continue operations.The accumulated deficit has grown to $148.107 million.The company explicitly states it expects to continue incurring net losses and will require additional financing, underscoring ongoing financial challenges.

Summary

  • Movano Inc. completed a one-for-ten (1-for-10) reverse stock split of its common stock, effective as of October 10, 2025, reducing outstanding shares from approximately 8.3 million to approximately 0.8 million.
  • The company re-published its audited consolidated financial statements for the years ended December 31, 2024, and December 31, 2023, to reflect the change in shares outstanding due to the reverse split.
  • The company has incurred significant losses from operations and generated negative cash flows from operating activities since inception, with an accumulated deficit of $148.1 million as of December 31, 2024.
  • The independent registered public accounting firm's report includes an explanatory paragraph relating to a going concern uncertainty.
  • Net loss for the year ended December 31, 2024, was $(23.727) million, an improvement from $(29.283) million in 2023.
  • Revenue for the year ended December 31, 2024, was $1.013 million, compared to $0 in 2023, primarily from sales of Evie Rings.
  • Cash and cash equivalents increased to $7.902 million as of December 31, 2024, from $6.118 million as of December 31, 2023.
  • Net cash used in operating activities was $(22.533) million in 2024, an improvement from $(26.177) million in 2023.
  • The company raised $24.325 million from financing activities in 2024, primarily through an April 2024 private placement.

Sentiment

Score: 3

Explanation: The filing highlights continued significant financial challenges, including recurring losses, a substantial accumulated deficit, and a going concern uncertainty, despite some revenue generation and capital raises. The overall financial health remains precarious.

Positives

  • Revenue generation commenced in 2024, with $1.013 million from Evie Ring sales, a significant step from $0 in 2023.
  • Net loss decreased to $(23.727) million in 2024 from $(29.283) million in 2023, indicating a reduction in losses.
  • Net cash used in operating activities improved to $(22.533) million in 2024 from $(26.177) million in 2023.
  • Cash and cash equivalents increased to $7.902 million at December 31, 2024, from $6.118 million at December 31, 2023.
  • Successfully raised $24.325 million through financing activities in 2024, providing capital for operations.

Negatives

  • The company has suffered recurring losses from operations and has a net capital deficiency, leading to an accumulated deficit of $148.1 million as of December 31, 2024.
  • The independent auditor's report includes an explanatory paragraph highlighting a substantial doubt about the company's ability to continue as a going concern.
  • Despite improvements, the company continues to experience negative cash flows from operating activities.
  • Net loss per share remains high at $(39.39) for 2024, reflecting ongoing unprofitability.
  • Significant operating expenses, including $11.195 million for research and development and $11.033 million for sales, general and administrative in 2024, continue to drive losses.

Risks

  • Substantial doubt about the company's ability to continue as a going concern due to recurring losses and a net capital deficiency.
  • Dependence on obtaining additional financing to fund future planned operations, including research and development and commercialization activities.
  • Risk that adequate additional financing may not be available on acceptable terms, or at all, which could force delays, reductions, or elimination of product development or commercialization efforts.
  • Reliance on third-party manufacturers to supply products for research and development, which could be adversely affected by significant interruptions in supply.
  • Concentration of credit risk with cash and cash equivalents held in United States financial institutions, with amounts exceeding federally insured limits.
  • Potential limitations on the company's ability to utilize net operating loss (NOL) and credit carryovers if an ownership change occurs as defined in Section 382 of the Internal Revenue Code.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future as it proceeds with the development of its technology. It anticipates requiring additional financing to fund future planned operations, including research and development and commercialization of its products.

Management Comments

  • "The Company expects to continue to incur net losses for the foreseeable future as it continues the development of its technology."
  • "The Company expects to require additional financing to fund its future planned operations, including research and development and commercialization of its products."
  • "The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies."

Industry Context

Movano Inc. operates in the highly competitive health tech and wearable device market, aiming to deliver medical-grade, high-quality data through consumer health devices like the Evie Ring. The company's current financial state, characterized by continued losses and a reliance on equity financing, is common for early-stage technology companies heavily invested in research and development prior to achieving significant market penetration and profitability. The challenge lies in scaling commercialization efforts while managing a high burn rate, a hurdle many innovative startups in this sector face.

Comparison to Industry Standards

  • The explicit 'going concern uncertainty' noted by the auditor is a significant indicator of financial distress, which is below industry standards for established, profitable companies but not uncommon for early-stage, pre-profit technology ventures.
  • The substantial accumulated deficit of $148.1 million and recurring net losses are typical for R&D-intensive health tech startups that have yet to achieve widespread commercial success and scale.
  • The company's reliance on frequent equity offerings for capital, including multiple public offerings in 2023 and a private placement in 2024, is a standard financing strategy for development-stage companies, but the volume suggests a high cash burn rate relative to current revenue generation.
  • The initiation of revenue from Evie Ring sales in 2024, albeit modest at $1.013 million, represents a critical milestone towards commercialization, a stage many pre-revenue startups in the wearable tech space strive to reach.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Authorized Shares IncreaseOn July 9, 2024, the company filed a Certificate of Amendment to increase the number of authorized shares of common stock from 150,000,000 to 500,000,000 shares.July 9, 2024Provides greater flexibility for future equity financing and stock-based compensation, potentially enabling larger capital raises or broader employee incentive programs.
Equity Incentive Plan Share IncreaseOn May 15, 2024, the Board approved, and on July 9, 2024, stockholders approved, an increase in the aggregate number of shares that may be issued pursuant to the 2019 Equity Incentive Plan from 89,333 to 156,000.July 9, 2024Enhances the company's ability to attract and retain talent through stock-based compensation, aligning employee incentives with company performance.

Legal Proceedings

  • Management is not currently aware of any litigation or administrative proceedings that may have a material adverse impact on the company's business, financial position, results of operations, or cash flows.

Related Party Transactions

  • Certain directors and officers participated in the April 2024 private placement, purchasing 1,918 units at an offering price of $84.80 per unit.

Stakeholder Impact

  • Shareholders: Face significant dilution from past and potential future equity raises. The multiple reverse stock splits (1-for-15 in Oct 2024, 1-for-10 in Oct 2025) are typically implemented to maintain listing requirements but can be perceived negatively. The explicit 'going concern uncertainty' poses a substantial risk to the value of their investment.
  • Employees: Benefit from stock-based compensation plans, but the company's precarious financial health and going concern uncertainty could impact job security and the long-term value of their equity awards.
  • Customers: The continued development and commercialization of products like the Evie Ring aim to provide valuable health information, but the company's financial instability could raise concerns about long-term product support, updates, and future innovation.
  • Creditors: The 'going concern uncertainty' and ongoing reliance on equity financing increase the risk profile for creditors, potentially affecting terms for future borrowings or trade credit.

Next Steps

  • Continue research and development activities for its technology platform and products.
  • Pursue commercialization activities for its products, such as the Evie Ring.
  • Seek additional financing through equity offerings, borrowings, or strategic alliances to fund future operations.

Key Dates

DateDescription
December 31, 2022Balance at this date for consolidated statements of stockholders equity.
February 6, 2023Completion of a $7.5 million underwritten public offering of common stock and warrants.
June 15, 2023Completion of a $9.2 million underwritten public offering of common stock.
August 2023Issuance of warrants to a third-party professional services firm.
November 17, 2023Completion of a $4.1 million underwritten public offering of common stock.
November 22, 2023Execution of a lease agreement for equipment.
December 31, 2023Fiscal year end for audited consolidated financial statements.
April 2, 2024Entered into a securities purchase agreement for a private placement of units.
April 5, 2024Closing of the April 2024 Private Placement.
May 15, 2024Board approved an increase in the aggregate number of shares for the 2019 Equity Incentive Plan.
May 2024Board approved the amendment of Preferred A and B Placement Warrants to extend maturity.
June 2024Replaced B. Riley Securities with Jones Trading as the Sales Agent for the At-the-Market Issuance Agreement.
June 19, 2024Executed the third amendment to the corporate office and facilities lease.
July 9, 2024Stockholders approved the increase in the aggregate number of shares for the 2019 Equity Incentive Plan.
July 9, 2024Filed a Certificate of Amendment increasing authorized common stock from 150,000,000 to 500,000,000 shares.
August 14, 2024Issued warrants in connection with a strategic advisory agreement.
October 1, 2024Commencement of the extended corporate office and facilities lease term.
October 29, 2024Completion of a 1-for-15 reverse stock split.
December 31, 2024Fiscal year end for audited consolidated financial statements.
April 4, 2025Date after which April 2024 warrants may be redeemed.
April 9, 2025Original date of Baker Tilly US, LLP's audit report.
April 2025Maturity of Preferred A and B Placement Warrants.
August 2025Maturity of Convertible Notes Placement Warrants.
October 10, 2025Effective date of the 1-for-10 reverse stock split.
December 19, 2025Date of the Current Report on Form 8-K and updated auditor's consent.
March 2026Maturity of Underwriter Warrants.
December 15, 2026Effective date for ASU 2024-03 (Income Statement Expense Disaggregation Disclosures) for fiscal years beginning after this date.
December 31, 2027End date of the extended corporate office and facilities lease term.
January 2028Maturity of January 2023 warrants.
February 2028Maturity of February 2023 warrants.
August 2028Maturity of August 2023 warrants.
April 2029Expiration of April 2024 warrants.
August 14, 2029Expiration date of August 2024 Warrants.

Recommendation

sell

The company faces substantial financial distress, evidenced by recurring significant losses, a large accumulated deficit, and an explicit 'going concern uncertainty' from its auditors. While revenue generation has begun and capital has been raised, the burn rate remains high, and the company explicitly states a need for further financing, which may not be available on favorable terms. The multiple reverse stock splits indicate a struggle to maintain share price and listing compliance. These factors collectively point to a high-risk investment with significant downside potential, making a 'Sell' recommendation appropriate for a seasoned investor.

Keywords

Movano, MOVE, SEC Filing, 8-K, Financial Statements, Reverse Stock Split, Going Concern, Wearable Technology, Health Tech, Evie Ring, Financial Results, Equity Offering, Capital Raise

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.